Startups channel feed – Endpoints News

Startups channel feed

In insulin resistance pact, Dewpoint adds Novo Nordisk to its pharma-rich pipeline

3 years ago

A $123M Flare will get Third Rock oncology biotech into the clinic this year

3 years ago

Exclusive: After getting his drug back, Landos founder assembles new startup for the big PhIII test

3 years ago

Kite's head of research leaves for Flagship startup Sonata

3 years ago

German biotech launches with ‘seamless’ gene editing platform built on evolving enzymes

3 years ago

Five pharmas back $85M Series A for Mediar's fibrosis-modulating antibodies

3 years ago

Eli Lilly, UCB and others Switch into gear with $52M for new RNA biotech

3 years ago

Updated: Carl Icahn proposes three new Illumina board members in proxy fight

3 years ago

Silicon Valley Bank customers to have all funds accessible, US says, easing biotech and tech turmoil

3 years ago

Versant's new immunology biotech Santa Ana Bio snags Series A with GV, TPG partners on board

3 years ago

ALS biotech QurAlis gets $88M boost from four pharmas for pair of PhI studies

3 years ago

Ampersand snags $50M as Flagship focuses therapeutics on desired targets only

3 years ago

Janssen's neuro division churns out Rapport, a new $100M biotech from Third Rock’s clinical data hunt

3 years ago

Tempus founders build a drug discovery startup, Pathos AI, with $40M in sight

3 years ago

Cell therapy biotech from Stanford CAR-T leader Crystal Mackall nabs $200M for PhII

3 years ago

Gene therapy startup Locanabio lays off staff, narrows focus on Duchenne

3 years ago

Third Rock shrinks another biotech as Cedilla restructures, CEO and CBO depart

3 years ago

A small Connecticut biotech throws hat into IPO ring

3 years ago

CAR-T biotech reduces staff as it hunts for capital to enter clinic next year

3 years ago

Exclusive: Sanofi, Astellas venture arms add cash to Avilar's 'ATAC' mission

3 years ago

'Rare outliers': Feng Zhang eyes a new path to genetic medicine delivery with ex-Alnylam leaders and $193M

3 years ago

Tillman Gerngross’ Amagma Therapeutics quietly ships antibodies to another biotech

3 years ago

Cell therapy biotech nabs Series A; Metagenome startup snags $77M round

3 years ago

PROTACs to RIPTACs: Arvinas founder snags $76M for next bet, Halda Therapeutics

3 years ago

First page Previous page 31 32 333435 36 37 Next page Last page